Fas Ligand Expression in Lynch Syndrome-Associated Colorectal Tumours

Jan J. Koornstra*, Steven de Jong, Wietske Boersma-van Eck, Nynke Zwart, Harry Hollema, Elisabeth G. E. de Vries, Jan H. Kleibeuker

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

Fas Ligand (FasL) expression by cancer cells may contribute to tumour immune escape via the Fas counterattack against tumour-infiltrating lymphocytes (TILs). Whether this plays a role in colorectal carcinogenesis in Lynch syndrome was examined studying FasL expression, tumour cell apoptosis and number of TILs in colorectal neoplasms from Lynch syndrome patients (50 adenomas, 20 carcinomas) compared with sporadic cases (69 adenomas, 52 carcinomas). FasL expression was observed in 94% of Lynch syndrome adenomas and in all carcinomas. FasL expression patterns and apoptotic indices were similar in Lynch syndrome-associated neoplasms and sporadic cases. The number of TILs was higher in Lynch syndrome neoplasms than in sporadic cases. There were no correlations between FasL expression and tumour cell apoptosis or number of TILs in Lynch syndrome-associated neoplasms. So, FasL expression is an early event in Lynch syndrome and sporadic colorectal carcinogenesis, but not related to TIL number. Taken together, our data do not support a role for the Fas counterattack in colorectal carcinogenesis in Lynch syndrome.

Original languageEnglish
Pages (from-to)399-406
Number of pages8
JournalPathology & oncology research
Volume15
Issue number3
DOIs
Publication statusPublished - Sep-2009

Keywords

  • Apoptosis
  • Colorectal cancer
  • Counterattack
  • Fas ligand
  • HNPCC
  • Lynch syndrome
  • MICROSATELLITE INSTABILITY STATUS
  • COLON-CANCER PATIENTS
  • INFILTRATING LYMPHOCYTES
  • IMMUNE PRIVILEGE
  • CELL APOPTOSIS
  • IN-VIVO
  • MALIGNANT-TRANSFORMATION
  • EARLY EVENT
  • T-CELLS
  • COUNTERATTACK

Cite this